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Abstract: PURPOSE To address the lack of prospective data on the real-life clinical application of trans-
arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society
of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Ther-
apy (CIRT). MATERIALS AND METHODS Patients were enrolled from 1 January 2015 till 31 December
2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary
or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on
the clinical context of TARE, overall survival (OS) and safety were collected. RESULTS Totally, 1027
patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients
received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall
survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for
hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver
metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic
cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4)
for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant
prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient
performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE
and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4
within 30 days after TARE. CONCLUSION In the real-life clinical setting, TARE is largely considered
to be a part of a palliative treatment strategy across indications and provides an excellent safety profile.
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Abstract
Purpose To address the lack of prospective data on the
real-life clinical application of trans-arterial radioem-
bolization (TARE) in Europe, the Cardiovascular and
Interventional Radiological Society of Europe (CIRSE)
initiated the prospective observational study CIRSE Reg-
istry for SIR-Spheres Therapy (CIRT).
Materials and Methods Patients were enrolled from 1
January 2015 till 31 December 2017. Eligible patients were
adult patients treated with TARE with Y90 resin micro-
spheres for primary or metastatic liver tumours. Patients
were followed up for 24 months after treatment, whereas
data on the clinical context of TARE, overall survival (OS)
and safety were collected.
Results Totally, 1027 patients were analysed. 68.2% of the
intention of treatment was palliative. Up to half of the
patients received systemic therapy and/or locoregional
treatments prior to TARE (53.1%; 38.3%). Median overall
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survival (OS) was reported per cohort and was 16.5 months
(95% confidence interval (CI) 14.2–19.3) for hepatocellular
carcinoma, 14.6 months (95% CI 10.9–17.9) for intrahep-
atic cholangiocarcinoma. For liver metastases, median OS
for colorectal cancer was 9.8 months (95% CI 8.3–12.9),
5.6 months for pancreatic cancer (95% CI 4.1–6.6),
10.6 months (95% CI 7.3–14.4) for breast cancer,
14.6 months (95% CI 7.3–21.4) for melanoma and
33.1 months (95% CI 22.1–nr) for neuroendocrine
tumours. Statistically significant prognostic factors in terms
of OS include the presence of ascites, cirrhosis, extra-
hepatic disease, patient performance status (Eastern
Cooperative Oncology Group), number of chemotherapy
lines prior to TARE and tumour burden. Thirty-day mor-
tality rate was 1.0%. 2.5% experienced adverse events
grade 3 or 4 within 30 days after TARE.
Conclusion In the real-life clinical setting, TARE is lar-
gely considered to be a part of a palliative treatment
strategy across indications and provides an excellent safety
profile.
Level of evidence Level 3.
Trial registration ClinicalTrials.gov NCT02305459.
Keywords Hepatocellular carcinoma  Metastasis 
Observational study  Registries  Therapeutic
embolization  Liver  Yttrium-90  Radioisotope
brachytherapy  Trans-arterial radioembolization
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Introduction
Current guidelines for the treatment of primary liver
malignancies (e.g. hepatocellular carcinoma (HCC), intra-
hepatic cholangiocarcinoma (ICC)) and hepatic metastases,
e.g. from colorectal cancer (mCRC), propose trans-arterial
radioembolization (TARE, also known as selective internal
radiation therapy (SIRT)) as an optional treatment modality
for patients with liver dominant disease not suitable for
surgical or ablative therapies, or who experienced no
response, significant side effects or intolerance when
treated with systemic therapies. [1–7].
At the time of the study’s conception in 2014, available
studies on TARE consisted of large cohort series and
smaller experimental trials [8–17]. In the meantime, sev-
eral large-scale randomized controlled trials on TARE in
mCRC and HCC have been completed and published
[18–22], as well as large prospective and retrospective
studies on HCC, ICC and mCRC [23–30]. As more centres
in Europe included TARE in their armamentarium of
treatments for liver malignancies, there was a need for a
multicentre, prospective data collection on the use of
TARE in clinical practice beyond high-expertise centres,
where countries with different health-care systems were
able to contribute to evaluate how TARE is used in stan-
dard clinical practice in Europe [31]. A recent multicentre
prospective observational study in the UK describes the
outcome of TARE in clinical practice for mCRC and ICC
[32, 33], and a large-scale prospective observational study
on TARE is currently being conducted in the USA
(NCT02685631). Physicians and patients will benefit from
the insights provided by real-world data from European
countries and from patients with other liver malignancies
beside HCC, mCRC and ICC. Data on less established uses
of TARE such as metastatic liver disease from tumour
entities such as breast cancer, malignant melanoma, or
pancreatic cancer would be needed to uncover potential
benefits of these specific patient groups [34–36].
To further improve the understanding of the real-life
clinical application of TARE in Europe, the Cardiovascular
and Interventional Radiological Society of Europe
(CIRSE) initiated the prospective CIRSE Registry for SIR-
Spheres Therapy (CIRT) for patients treated with TARE
with Y90 resin microspheres (SIR-Spheres Y-90 resin
microspheres, Sirtex Medical Pty Limited; St. Leonards,
NSW, Australia). Besides data on how TARE is embedded
in the real-life clinical practice (primary objective), CIRT
collected data on safety, effectiveness (overall survival
(OS), progression-free survival (PFS), liver-specific PFS
and imaging response), quality of life (QOL) and details
concerning the treatment application.
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This manuscript specifically discusses data concerning
real-life application of TARE, therapeutic outcome (in
terms of overall survival) and safety (in terms of 30-day
mortality and morbidity) for all indications. Future manu-
scripts will include further analysis of the CIRT data
considering, e.g. dosimetry data, PFS, hepatic-PFS, imag-
ing response and QOL, as well as subgroup analyses per
indication, including less evaluated indications like liver




CIRT is a prospective, multicentre, single-device, obser-
vational study of patients with hepatic malignancies treated
with TARE with Y90 resin microspheres as standard of
care. As observational study, CIRT did not prescribe or
encourage the use of TARE in a particular patient group,
but observed its use in the real-life clinical setting. Sites
were invited to participate if TARE was in their arma-
mentarium of treatment options to treat hepatic malignan-
cies, and if they met the minimum selection criteria of at
least 40 treatments in total, with a minimum of ten pro-
cedures within 12 months prior to invitation. From August
2014 to April 2017, 68 sites from 12 countries were invited
to participate, of whom 27 included patients, representing
five countries in the European Union, Switzerland, Turkey
and Israel (see Supplement 1 and Supplement 2).
A detailed manuscript on the methodology of CIRT has
been previously reported [37].
Patient inclusion criteria were: the patient was 18 years
or older, diagnosed with primary or metastatic liver
malignancies, scheduled to be treated with TARE with Y90
resin microspheres. There were no specific exclusion cri-
teria. All included patients signed the informed consent
form. Patient recruitment occurred between 1 January 2015
and 31 December 2017. Follow-up data was collected until
31 December 2019; patients were followed up for
24 months or until study exit. Specific follow-up intervals
were left to the discretion of the medical teams. It was
recommended that patient follow-up data would be col-
lected every 3 months. In case follow-up evaluations were
not performed at the site of the TARE treatment, sites were
encouraged to obtain follow-up information from referring
physicians.
Assessments
The real-life usage of TARE is determined by evaluating
the intention of the treatment per indication, and how the
TARE treatment was embedded in between prior and post-
interventional hepatic and systemic therapies. Overall
survival was measured from day of TARE treatment until
date of death. Safety outcomes are described as 30-day
morbidity and mortality rates according to the Common
Terminology Criteria for Adverse Events, version 5.0.
Monitored serious adverse events (SAEs, grade 3 and 4)
were abdominal pain, fatigue, fever, nausea, vomiting,
gastrointestinal ulceration, gastritis, radiation cholecystitis
and radioembolization-induced liver disease (REILD).
Patient characteristics, prior treatments and volumetric data
were collected around time of treatment. Post-TARE
treatments and safety data were collected at every follow-
up. Survival status was collected as information became
available.
Bias
As observational study, CIRT is sensitive to selection bias.
This was addressed by contractually agreeing with study
sites that all consecutive cases would be included. Regular
remote monitoring by the CIRSE Clinical Research
Department was done to verify if sites included all of their
cases and to address missing data and data queries. How-
ever, it was not possible to perform source document
verification.
Statistical Analysis
Data regarding the primary endpoint, safety and overall
survival (OS) data are presented by summaries and
descriptive statistics. Overall survival is presented graphi-
cally as Kaplan–Meyer curves and median time-to-event
per indication with 95% confidence intervals (CI) being
provided. Cox multiple regression is used to assess the
impact of the covariates for OS and hazard ratios (HR),
95% CI and p-values are provided for all covariates.
Covariates were chosen prior to data analysis and were
published in a methodology manuscript [37]. P-values
of\ 0.05 are considered statistically significant. Patients
who had withdrawn consent or are lost to follow up are
censored at the last time they were documented as being
alive (OS). All available data are used, and no imputations
of missing data are made. Where missing data were
observed, it was explained in the summary tables.
All procedures performed were in accordance with the
ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki Declaration
and its later amendments or comparable ethical standards.
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Results
Data from 1050 patients were included in the study.
Twenty-three patients were excluded (see Supplement 3).
The treated cohort (1027) consisted of 542 (52.8%) patients
with primary liver tumours (HCC 422 (41.2%), ICC 120
(11.6%)) and 485 (47.2%) with metastatic liver disease
(mCRC 237 (23.1%), neuroendocrine (NET) 58 (5.6%),
breast 47 (4.6%) and pancreatic cancer and melanoma 32
each (3.1%), and other metastases 79 (7.7%)). 64.9% of the
patients were male, and the median age was 65 years (in-
terquartile range (IQR) 56–72).
Patient Characteristics and Real-Life Application
Primary Liver Tumours
For patients with primary liver tumours, the Eastern
Cooperative Oncology Group (ECOG) status was 0 in
58.5% of the patients, with 8.3% having ECOG 2 or higher
(Table 1). The presence of ascites was observed in 14.3%
of the patients, while cirrhosis was more frequently
observed in patients with HCC, 71.1% versus 12.5% in
ICC. On the other hand, in patients with ICC, extra-hepatic
disease was observed in 30% of the cases versus 9.5% of
HCC patients. In patients with HCC, unilateral (right-
sided) liver tumours were found in 50.2% of the cases,
compared to 27.5% in the ICC cohort, which saw more
bilobar liver tumours (59.2%). In total, portal vein throm-
bosis was found in 30.5% of the cases.
In the primary liver cancer cohorts, median time from
diagnosis to TARE was 188 days (IQR 71–590) for HCC
and 201 (IQR 65–468) for ICC (Table 2). 60.0% received
TARE with palliative intentions (non-curative, e.g. to
prolong freedom from or relief of cancer-related symp-
toms); tumour downsizing was intended in 29.9% of the
cases. In the HCC cohort, prior systemic treatments were
provided in 10.7% of the patients, while 44.8% receive
some form of prior locoregional treatments such as trans-
arterial chemoembolization (TACE) (23.0%) or surgery
(17.1%). In contrast, ICC patients received prior systemic
treatment in 60.8% of the cases [39.2% received combined
regimens based on gemcitabine (see Supplement 4)] and
locoregional treatments in 34.2%, primarily in the form of
surgical procedures (26.7%). Less than 10% of the primary
cancer patients received systemic therapies in a concomi-
tant setting. Following TARE, 31.4% received further
systemic treatment: in patients with HCC, 18.9% and 4.5%
underwent treatment with a tyrosine kinase inhibitor (TKI)
and/or other treatments, respectively. Locoregional treat-
ments were applied in 18.4% of the primary liver cases.
Metastatic Liver Tumours
In patients with metastatic liver tumours, ECOG 0 was
observed in 58.4% of the patients (Table 3). Extra-hepatic
disease was present in 52.8% of the patients, but ascites
and cirrhosis were observed in 4.9% and 1.2% of the
patients, respectively. Most of the patients (73.6%) had
bilobar tumour burden with a liver to tumour percentage of
10.5%. Portal vein thrombosis was observed in 2.6% of the
cases.
Median time from diagnosis of the liver metastases to
TARE was 579 days (IQR 253–1089) for the complete
metastatic cohort, ranging between 84 days (IQR 56–315)
for melanoma metastases to 1242 days (IQR 441–2196) in
NET (Table 4). Similar to the primary liver tumour cohort,
the intention of TARE was palliative in 77.3% of the
patients and downsizing of the tumour in 15.3%. 88.0% of
the patients received systemic treatment, and 33.6%
received locoregional treatment prior to TARE. 13.2% of
the patients received systemic treatments in a concomitant
setting. After TARE, systemic treatment was applied in
35.1% of the patients. 13.8% received locoregional
treatments.
Overall Survival
During the observation period, 495 (48.2%) patients died
and 349 (33.9%) were lost to follow up. 26 (2.5%) patients
had less than 2 years of follow-up but no recorded reason
for non-completion. 157 (15.3%) patients were alive and
completed the 2-year follow-up period (see Supplement 5).
Median overall survival for patients following TARE
was 16.5 months (95% CI 14.2–19.3) for HCC and
14.7 months (95% CI 10.9–17.9) for ICC. For liver
metastases, median OS for mCRC was 9.8 months (95% CI
8.3–12.9), 5.6 months (95% CI 4.1–6.6) for pancreatic
cancer metastases, 10.6 months (95% CI 7.3–14.4) for
breast cancer, 14.6 months (95% CI 7.3–21.4) for mela-
noma and 33.1 months (95% 22.1–nr) for neuroendocrine
tumours (see Fig. 1).
For the whole cohort, covariate analyses showed that
extra-hepatic disease and ECOG status C 0 were associ-
ated with a lower survival rate (HR 1.372, 95% CI
1.149–1.638, p\ 0.0001; HR 1.513, 95% CI 1.280–1.789,
for ECOG 1 and HR 1.624, 95% CI 1.217–2.168 for ECOG
2, p\ 0.0001, respectively), as well as the presence of
cirrhosis (HR 1.304, 95% CI 1.063–1.599, p = 0.0128) and
ascites (HR 1.344, 95% CI 1.035–1.746, p = 0.0039).
Unilateral malignancies had a better survival outcome than
bilobar malignancies (HR 0.790, 95% CI 0.589–1.059 for
left liver lobe tumours and HR 0.694, 95% CI 0.572–0.843
for right liver lobe tumours, p = 0.0024), and a higher
tumour burden was negatively associated with survival
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(HR 1.414, 95% CI 1.143–1.750, p = 0.0195 was found for
a tumour to liver percentage of more than 20%). Prior
systemic chemotherapy (yes/no) did not qualify as a sig-
nificant prognostic factor (p = 0.2068); however, the
number of chemotherapy lines prior to TARE was found to
be statistically significant (increased HR compared to no
prior chemotherapy, p\ 0.0001). Covariates as sex,
number of liver tumours and prior hepatic procedures did
not produce any significant differences in results (p-val-
ues[ 0.05, see Table 5).
Safety
Across the entire cohort, the 30-day mortality rate of
patients that received TARE was 1.0% (n = 10, (see Sup-
plement 5). Serious adverse events (SAE, grade 3 and 4)
within 30 days of treatment were found in less than 2.5%
of the patients. SAEs such as gastritis, gastrointestinal
ulcerations, radiation cholecystitis and radioembolization-
induced liver disease (REILD) occurred in less than 0.3%
of the total patient cohort.
Discussion
The results reported here derive from the largest prospec-
tive study on TARE to date and provide a good represen-
tation of the European application of TARE in its diverse
clinical context. This study provides valuable information
on the real-life clinical application and outcomes of TARE
in indications for which guidelines are available and used
(HCC, ICC, mCRC), as well as insights in the less estab-
lished use of TARE in liver metastases of NET, breast
cancer, pancreatic cancer and melanoma.
The data indicate that in the real-life clinical setting,
TARE is largely considered to be a part of a palliative
treatment strategy, across indications. That is to say to
prolong freedom from or relief of cancer-related symp-
toms. The relatively low number of patients receiving any
systemic therapy (33.1%) or loco-regional treatments
(16.3%) after TARE suggests that TARE is used as ‘‘last
meaningful treatment’’ rather than being planned as an
early consolidation in the scope of various treatment
options, suggesting that TARE is used according to most of
Table 1 Patient characteristics–primary tumours
Category Subcategory HCC (n = 422) ICC (n = 120) All (n = 542)
ECOG status 0–fully active 252 (59.7%) 65 (54.2%) 317 (58.5%)
1–restricted 136 (32.2%) 41 (34.2%) 177 (32.7%)
2 or higher 34 (8.1%) 11 (9.2%) 45 (8.3%)
Missingb – 3 (2.5%) 3 (0.6%)
Extra-hepatic disease No 382 (90.5%) 84 (70.0%) 466 (86.0%)
Yes 40 (9.5%) 36 (30.0%) 76 (14.0%)
Ascites No 357 (84.6%) 107 (89.2%) 464 (85.7%)
Yes 65 (15.4%) 13 (10.8%) 78 (14.3%)
Cirrhosis No 122 (28.9%) 105 (87.5%) 227 (41.9%)
Yes 300 (71.1%) 15 (12.5%) 315 (58.1%)
Location of liver tumours Bilobar 159 (37.7%) 71 (59.2%) 230 (42.4%)
Left only 51 (12.1%) 16 (13.3%) 67 (12.4%)
Right only 212 (50.2%) 33 (27.5%) 245 (45.2%)
Number of liver tumours 1 110 (26.1%) 32 (26.7%) 142 (26.2%)
2–5 154 (36.5%) 35 (29.2%) 189 (34.9%)
6–9 23 (5.5%) 10 (8.3%) 33 (6.1%)
10 or more 55 (13.0%) 10 (8.3%) 65 (12.0%)
Uncountable 80 (19.0%) 33 (27.5%) 113 (20.8%)
Portal vein Patent 282 (66.8%) 95 (79.2%) 377 (69.6%)
Segmental thrombosis 82 (19.4%) 14 (11.7%) 96 (17.8%)
Lobar thrombosis 38 (9.0%) 7 (5.8%) 45 (8.3%)
Main thrombosis 20 (4.7%) 4 (3.3%) 24 (4.4%)
Total tumour to liver percentage Median 9.2% 12.8% 10.0%
Q1, Q3 3.4%, 20.2% 7.9%, 21.5% 4.4%, 20.4%
Missing 67 (15.9%) 23 (19.2%) 90 (16.7%)
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the current European guidelines [1–5]. Our reported safety
data confirming a favourable toxicity profile of TARE may
support the consideration of its use earlier in the
armamentarium.
Considering the timing of the TARE treatment in rela-
tion to prior systemic therapies, our study reported that the
majority of the metastatic liver malignancies (mCRC,
NET, breast and pancreatic) were treated with TARE after
one or more systemic therapy line (Supplement 2). For
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mCRC, studies have shown that good results can still be
achieved in heavily pre-treated patients (see below)
[38–40]. In NET, TARE can be considered for patients not
responding to systemic therapies or have undergone prior
peptide receptor radionuclide therapy (PRRT), TACE or
bland embolization, which is reflected in the long median
time from metastatic diagnosis to TARE (1242 days,
Table 4) [35, 41, 42]. Due to the high OS generally found
in NET patients, care should be taken in applying TARE in
NET, as treatment-related deaths have been observed in
this patient population [43]. For hepatic breast cancer
malignancies, all patients in this study were reported to
have received prior systemic therapy and most of them
received TARE with palliative intent, which have shown to
delay progression and decrease tumour size [44–46]. The
timing of TARE in pancreatic and melanoma liver metas-
tases is less well understood [47–49]. A Finnish retro-
spective study on TARE in melanoma patients with hepatic
metastases achieved a median OS for TARE of
18.7 months as a first-line treatment compared to
chemotherapy (10.5 months), which is reflected in our
Table 3 Real-life application—primary tumours
Category Subcategory HCC (n = 422) ICC (n = 120) All (n = 542)
Time since primary diagnosis (days) Median 188 201 191
Q1, Q3 71, 590 65, 468 70, 652
Missing 4 (0.9%) 2 (1.7%) 6 (0.1%)
Intention of treatmentc Ablation 17 (4.0%) 7 (5.8%) 24 (4.4%)
Bridge to liver surgery 3 (0.7%) 3 (2.5%) 6 (1.1%)
Bridge to liver transplant 23 (5.5%) 2 (1.7%) 25 (4.6%)
Downsizing / down-staging 137 (32.5%) 25 (20.8%) 162 (29.9%)
Palliative 242 (57.3%) 83 (69.2%) 325 (60.0%)
Prior TARE hepatic procedures Yes 189 (44.8%) 41 (34.2%) 230 (42.4%)
No 233 (55.2%) 79 (65.8%) 312 (57.6%)
Surgical (any)a 72 (17.1%) 32 (26.7%) 104 (19.2%)
Ablation (any) 62 (14.7%) 7 (5.8%) 69 (12.7%)
TACE (any) 97 (23.0%) 2 (1.7%) 99 (18.3%)
Vascular (any) 15 (3.6%) 1 (0.8%) 16 (3.0%)
Abdominal radiotherapy (any) 7 (1.7%) 5 (4.2%) 12 (2.2%)
Prior systemic therapy Yes 45 (10.7%) 73 (60.8%) 118 (21.8%)
No 377 (89.3%) 47 (39.2%) 424 (78.2%)
Concomitant chemotherapyb Yes 32 (7.6%) 11 (9.2%) 43 (7.9%)
No 390 (92.4%) 109 (90.8%) 499 (92.1%)
Post-TARE systemic therapy Yes 125 (29.6%) 45 (37.5%) 170 (31.4%)
No 262 (62.1%) 63 (52.5%) 325 (60.0%)
Missingd 35 (8.3%) 12 (10.0%) 47 (8.7%)
Post-TARE hepatic procedures Yes 80 (19.0%) 20 (16.7%) 100 (18.4%)
No 307 (72.7%) 88 (73.3%) 395 (72.9%)
Missingd 35 (8.3%) 12 (10.0%) 47 (8.7%)
Surgical (any)a 3 (0.7%) 4 (3.3%) 7 (1.3%)
Ablation (any) 11 (2.6%) 4 (3.3%) 5 (2.8%)
TACE (any) 34 (8.1%) 1 (0.8%) 35 (6.5%)
Vascular (any) 7 (1.7%) 2 (1.7%) 9 (1.7%)
Abdominal radiotherapy (any) 13 (3.1%) 6 (5.0%) 19 (3.5%)
aPatients can have multiple prior and post-TARE hepatic procedures
bConcomitant if systemic therapy start date is within 4 weeks of first TARE treatment start date and up to 8 weeks after first TARE end date
(where end date is within 42 days of first TARE in case of two sessions)
cIntention of TARE is for first treatment
dMissing data include data from patients that were lost to follow up or deceased before the first follow-up could be included (n = 47)
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reported median time from diagnosis to TARE of 84 days
[50].
For our primary cohorts, TARE was provided consid-
erably earlier in the treatment pathway (median 188 days
(IQR 71–590) for HCC and median 201 days (IQR
65–468) for ICC), suggesting fewer prior hepatic treat-
ments or systemic therapies. Indeed, current guideline
recommendations on HCC suggest TARE fairly early in
the treatment pathway [4, 7]. For ICC, TARE is recom-
mended after at least 1 line of systemic therapy in locally
advanced and metastatic ICC [2]. A recent retrospective
study by Bargellini et al. suggests no significant differ-
ences between OS between chemotherapy naı̈ve patients
and patients who received prior first-line chemotherapy
(with and without progression) [30]. A phase 2 trial by
Edeline et al. found a median OS of 22 months in
chemotherapy naı̈ve patients treated with glass TARE and
concomitant chemotherapy, suggesting that administering
TARE early in the treatment pathway of unresectable ICC
could be beneficial [51]. In our results, prior systemic
therapy was provided to 60.8% of the patients, suggesting
that sites may have different approaches concerning the
place of TARE in the treatment pathway of patients with
ICC.
It is encouraging that the median OS for the different
cohorts found in our study is consistent with findings of
other studies: in mCRC treated with TARE, White et al.
reported a pooled weighted OS of 9.6 months (23 studies,
n = 2517, 95% CI 8.9–10.4) [33], which is consistent with
our findings (OS 9.8 months, 95% CI 8.3–12.9). For the
smaller cohorts neuroendocrine, breast, pancreatic and
melanoma liver metastases, the median OS found in this
study were comparable with the median OS found in other
studies (breast, a systematic review of 12 studies (n = 452)
found an OS of 11.3 months [52]; neuroendocrine, a sys-
tematic review of 18 studies (n = 870) found a median OS
of 27.6 months [42]; pancreatic, OS 5.5 months [48];
melanoma, OS 19.9 months [53] and 18.7 months [50]).
This supports the fact that the real-life clinical application
of TARE in metastatic liver tumours is in accordance with
current evidence and strengthens the expectations regard-
ing survival for patients treated with TARE for these
indications.
For primary tumours, systematic reviews from Al-Adra
et al. and Boehm et al. reported a median OS of
15.5 months (range 7–22.2 months) and 13.9 months (95%
CI 9.5–18.3), respectively [54, 55]. Our ICC cohort pre-
sented an OS well within the expected range of survival for
patients with ICC treated with TARE (14.7, 95% CI
10.9–17.9). For HCC, RCTs such as SARAH, SIRveNIB
and SORAMIC found median OS of 8.0, 8.8 and
12.1 months, respectively [18, 22, 56], while retrospective
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high median OS (16.5 months) can be explained by our
high number of Child-Turcotte-Pugh (CTP) A (81.4%)
versus CTP B (18.0%) (see supplement 3) paralleling the
data presented by Salem et al. [58] and Sangro et al. [29].
Our study confirms previous findings that independent
of indication, prognostic factors commonly associated with
an increased survival rate are ECOG 0, reduced tumour
burden, lack of cirrhosis and ascites, low number of
chemotherapy lines prior to TARE and no extra-hepatic
disease [16, 57, 59–62]. Kurilova et al. have shown that in
mCRC patients in the salvage setting, 1-year OS can range
from 10% to 90% based on independent baseline parame-
ters (number of extra-hepatic disease sites, carcinoembry-
onic antigen, albumin, alanine aminotransferase level,
tumour differentiation level and the sum of the two largest
tumour diameters) [38]. Damm et al. have developed a
scoring system for patients with mCRC consisting of a
combination of tumour load, CEA or CA19-9 levels and
Karnofsky index to improve patient selection for TARE
[39]. In HCC, the presence of portal vein thrombosis has
been identified as a negative prognosticator for survival
and will be evaluated in a subsequent subgroup analysis
[63, 64]. Potential other prognostic factors such as time
from (metastatic) diagnosis to treatment and tumour
markers were not evaluated at this time.
Limitations of this study are the observational design,
whereas potentially important confounding factors could
not be controlled. The relatively high number of patients
that were lost to follow up can introduce bias regarding the
interpretation of OS. A potential explanation might be the
fact that TARE requires a comprehensive infrastructure
with patients being referred to specialised centres for the
treatment while being followed up by their local physician.
Follow-up information was in those cases obtained by
contacting the referring physician or, if this was not pos-
sible, the patient was considered as lost to follow up. While
it was outside of the scope of the study to improve the
necessary infrastructure for interventional radiology to
follow up on their patients, this study provides an oppor-
tunity to reflect on the necessity for interventional radiol-
ogists to initiate follow-up standards and order relevant
imaging after TARE. The CIRSE initiative Standards of
Table 5 Covariate analysis
Covariate Level Events (%) HR estimatea 95% CI p valueb
ECOG 0-Fully active 58.7% (352/600) 1.000
1-Restricted 73.2% (246/336) 1.513 [1.280, 1.789] \ 0.0001
2 or higher 70.0% (56/80) 1.624 [1.217, 2.168]
Extra-hepatic disease prior to treatment No 59.0% (426/722) 1.000
Yes 76.7% (234/305) 1.372 [1.149, 1.638] \ 0.0001
Cirrhosis No 65.6% (463/706) 1.000
Yes 61.4% (197/321) 1.304 [1.063, 1.599] 0.0128
Ascites No 63.6% (588/925) 1.000
Yes 70.6% (72/102) 1.344 [1.035, 1.746] 0.0039
Tumour to liver percentage Less than 10% 59.0% (242/410) 1.000
10%–20% 62.0% (127/205) 1.137 [0.914, 1.413] 0.0195
Greater than 20% 66.8% (147/220) 1.414 [1.143, 1.750]
Unknown 75.0% (144/192) 1.098 [0.879, 1.373]
Location of liver tumours Bilobar 71.4% (419/587) 1.000
Left only 57.0% (57/100) 0.790 [0.589, 1.059] 0.0024
Right only 54.3% (184/339) 0.694 [0.572, 0.843]
Prior chemotherapy: number of lines 0 57.4% (296/516) 1.000
1 64.4% (123/191) 1.176 [0.931, 1.485] \ 0.0001
2–5 76.8% (172/224) 1.855 [1.493, 2.303]
6 or more 72.5% (66/91) 1.355 [1.010, 1.818]
aA hazard ratio above 1 implies a higher rate of non-survival for that category compared to the reference category (for which the hazard ratio is
1.000). Selection of covariates based on a stepwise procedure. Variables that did not qualify (p[ 0.05) were: sex (p = 0.2800), prior systemic
therapy (p = 0.2664), prior hepatic procedures (p = 0.0895) and number of liver tumours (p = 0.0964)
bP values are from global Wald test
bFig. 1 Kaplan–Meier curves per indication of overall survival in
months after TARE, including at risk patients per interval
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Quality Assurance in Interventional Oncology is an ini-
tiative to improve quality assurance in interventional
oncology, amongst which post-intervention follow-ups and
imaging are one of the quality standards [70] Another
limitation has been the timing of the study. In the last
years, research on TARE has provided insights in the
importance of biomarkers, genetic information and tumour
absorbed dose on the oncological outcomes [39, 65–69]. As
CIRT was designed before these insights were accepted
and applied, data on these outcomes have not been inclu-
ded in the objectives of the study. Finally, this analysis did
not take into account the potential differences of national
guidelines, reimbursement policies and standards of
practice.
Conclusion
This large-scale prospective observational study confirmed
that TARE is safe and effective in the real-life clinical
setting across various indications. In the real-life clinical
setting, TARE is largely considered to be a part of a pal-
liative treatment strategy and less as a component of early
consolidation. Real-life OS is comparable to the results
from prior clinical trials. Careful patient selection, also in
the salvage setting, has been shown to be essential in the
treatment liver malignancies with TARE. As new therapies
like immune-oncology become available and synergistic
treatment concepts get further accepted, TARE will likely
become more and more integrated in the standard arma-
mentarium of oncological treatment regimen.
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50. Tulokas S, Mäenpää H, Peltola E, et al. Selective internal radi-
ation therapy (SIRT) as treatment for hepatic metastases of uveal
melanoma: a Finnish nation-wide retrospective experience. Acta
Oncol (Madr). 2018. https://doi.org/10.1080/0284186X.2018.
1465587.
51. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus
chemotherapy for first-line treatment of locally advanced intra-
hepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA
Oncol. 2020. https://doi.org/10.1001/jamaoncol.2019.3702.
52. Feretis M, Solodkyy A. Yttrium-90 radioembolization for unre-
sectable hepatic metastases of breast cancer: a systematic review.
World J Gastrointest Oncol. 2020. https://doi.org/10.4251/wjgo.
v12.i2.228.
34 T. Helmberger et al.: Clinical Application of Trans-arterial Radioembolization in Hepatic…
123
53. Xing M, Prajapati HJ, Dhanasekaran R, et al. Selective internal
yttrium-90 radioembolization therapy (90Y-SIRT) versus best
supportive care in patients with unresectable metastatic mela-
noma to the liver refractory to systemic therapy: Safety and
efficacy cohort study. Am J Clin Oncol Cancer Clin Trials. 2017.
https://doi.org/10.1097/COC.0000000000000109.
54. Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS.
Treatment of unresectable intrahepatic cholangiocarcinoma with
yttrium-90 radioembolization: a systematic review and pooled
analysis. Eur J Surg Oncol. 2015. https://doi.org/10.1016/j.ejso.
2014.09.007.
55. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative
effectiveness of hepatic artery based therapies for unre-
sectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015.
https://doi.org/10.1002/jso.23781.
56. Ricke J, Sangro B, Amthauer H, et al. The impact of combining
Selective Internal Radiation Therapy (SIRT) with Sorafenib on
overall survival in patients with advanced hepatocellular carci-
noma: the soramic trial palliative cohort. J Hepatol. 2018. https://
doi.org/10.1016/s0168-8278(18)30424-0.
57. Abdallah MA, Wongjarupong N, Hassan MA, et al. The efficacy,
safety, and predictors of outcomes of transarterial radioem-
bolization for hepatocellular carcinoma: a retrospective study.
Expert Rev Gastroenterol Hepatol. 2020. https://doi.org/10.1080/
17474124.2020.1777856.
58. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt
Y90 as primary treatment for hepatocellular carcinoma informed
by a 1000-patient 15-year experience. Hepatology. 2018. https://
doi.org/10.1002/hep.29691.
59. Abouchaleh N, Gabr A, Ali R, et al. 90 Y radioembolization for
locally advanced hepatocellular carcinoma with portal vein
thrombosis: Long-term outcomes in a 185-patient cohort. J Nucl
Med. 2018. https://doi.org/10.2967/jnumed.117.199752.
60. Reimer P, Virarkar MK, Binnenhei M, Justinger M, Schön MR,
Tatsch K. Prognostic factors in overall survival of patients with
unresectable intrahepatic cholangiocarcinoma treated by means
of yttrium-90 radioembolization: results in therapy-naı̈ve
patients. Cardiovasc Intervent Radiol. 2018. https://doi.org/10.
1007/s00270-017-1871-2.
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